Carina L. Bos

1.8k total citations
17 papers, 1.4k citations indexed

About

Carina L. Bos is a scholar working on Molecular Biology, Pharmacology and Pathology and Forensic Medicine. According to data from OpenAlex, Carina L. Bos has authored 17 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 4 papers in Pharmacology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Carina L. Bos's work include Systemic Lupus Erythematosus Research (4 papers), Bioactive Compounds and Antitumor Agents (2 papers) and Biological Stains and Phytochemicals (2 papers). Carina L. Bos is often cited by papers focused on Systemic Lupus Erythematosus Research (4 papers), Bioactive Compounds and Antitumor Agents (2 papers) and Biological Stains and Phytochemicals (2 papers). Carina L. Bos collaborates with scholars based in Netherlands, Brazil and Germany. Carina L. Bos's co-authors include Maikel P. Peppelenbosch, Dick J. Richel, Henri H. Versteeg, Tita Ritsema, James C.H. Hardwick, Liudmila L. Kodach, Nelsón Durán, Sander H. Diks, Carmen Verı́ssima Ferreira and Lisa G. M. van Baarsen and has published in prestigious journals such as Blood, The Journal of Immunology and PLoS ONE.

In The Last Decade

Carina L. Bos

17 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carina L. Bos Netherlands 14 473 267 212 205 189 17 1.4k
Shiro Nakaike Japan 23 414 0.9× 163 0.6× 90 0.4× 277 1.4× 86 0.5× 77 1.6k
Song Xu China 26 893 1.9× 191 0.7× 170 0.8× 163 0.8× 58 0.3× 65 1.6k
Lorenza Trabalzini Italy 26 809 1.7× 101 0.4× 171 0.8× 174 0.8× 48 0.3× 71 1.9k
Bruna Pucci Italy 19 986 2.1× 106 0.4× 461 2.2× 140 0.7× 56 0.3× 26 1.9k
Xin Wu China 19 793 1.7× 114 0.4× 249 1.2× 232 1.1× 43 0.2× 44 1.5k
Hui‐Chiu Chang Taiwan 31 1.3k 2.8× 235 0.9× 555 2.6× 138 0.7× 98 0.5× 52 2.4k
Lucia Trevisi Italy 20 567 1.2× 121 0.5× 137 0.6× 212 1.0× 66 0.3× 43 1.2k
My‐Hanh Lam United States 21 857 1.8× 193 0.7× 388 1.8× 148 0.7× 56 0.3× 33 2.0k
Byung‐Doo Hwang South Korea 24 862 1.8× 268 1.0× 208 1.0× 142 0.7× 41 0.2× 73 1.7k
Mohamed Ouzzine France 26 916 1.9× 147 0.6× 280 1.3× 91 0.4× 25 0.1× 64 1.7k

Countries citing papers authored by Carina L. Bos

Since Specialization
Citations

This map shows the geographic impact of Carina L. Bos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carina L. Bos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carina L. Bos more than expected).

Fields of papers citing papers by Carina L. Bos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carina L. Bos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carina L. Bos. The network helps show where Carina L. Bos may publish in the future.

Co-authorship network of co-authors of Carina L. Bos

This figure shows the co-authorship network connecting the top 25 collaborators of Carina L. Bos. A scholar is included among the top collaborators of Carina L. Bos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carina L. Bos. Carina L. Bos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Vosslamber, Saskia, Carina L. Bos, Joyce Lübbers, et al.. (2014). A1.77 Interferon regulatory factor 5 (IRF5) gene variant RS2004640 is associated with carotid intima media thickness in rheumatoid arthritis patients. Annals of the Rheumatic Diseases. 73. A34–A34. 3 indexed citations
2.
Dihal, Ashwin A., Carina L. Bos, Philip W. Voorneveld, et al.. (2011). 5-aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer. Gut. 61(12). 1708–1715. 27 indexed citations
3.
Thurlings, Rogier M., Janneke Tekstra, J.A. van Roon, et al.. (2010). Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis & Rheumatism. 62(12). 3607–3614. 100 indexed citations
4.
Bos, Carina L., Lisa G. M. van Baarsen, Trieneke C. G. Timmer, et al.. (2009). Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. Genes and Immunity. 10(3). 210–218. 36 indexed citations
5.
Cantaert, Tineke, Lisa G. M. van Baarsen, Carla A. Wijbrandts, et al.. (2009). Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Lara D. Veeken. 49(1). 156–166. 31 indexed citations
6.
Ritsema, Tita, Sander H. Diks, Carina L. Bos, et al.. (2009). Are Small GTPases Signal Hubs in Sugar-Mediated Induction of Fructan Biosynthesis?. PLoS ONE. 4(8). e6605–e6605. 32 indexed citations
7.
Baarsen, Lisa G. M. van, et al.. (2009). Transcription profiling of rheumatic diseases. Arthritis Research & Therapy. 11(1). 207–207. 32 indexed citations
8.
Medema, Jan Paul, Carina L. Bos, Aldo Jongejan, et al.. (2007). Chemical Insights in the Concept of Hybrid Drugs:  The Antitumor Effect of Nitric Oxide-Donating Aspirin Involves A Quinone Methide but Not Nitric Oxide nor Aspirin. Journal of Medicinal Chemistry. 50(10). 2424–2431. 131 indexed citations
9.
Souza, Ana Carolina Santos de, Liudmila L. Kodach, Fernanda Ramos Gadelha, et al.. (2006). A promising action of riboflavin as a mediator of leukaemia cell death. APOPTOSIS. 11(10). 1761–1771. 46 indexed citations
10.
Bos, Carina L., Sander H. Diks, James C.H. Hardwick, et al.. (2006). Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/ -catenin pathway activity. Carcinogenesis. 27(12). 2371–2382. 63 indexed citations
11.
Ferreira, Carmen Verı́ssima, Henri H. Versteeg, Cristiane Fernandes de Assis, et al.. (2006). Tetrahydroxyquinone induces apoptosis of leukemia cells through diminished survival signaling. Experimental Hematology. 34(2). 188–196. 5 indexed citations
12.
Bos, Carina L., Liudmila L. Kodach, Gijs R. van den Brink, et al.. (2006). Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 25(49). 6447–6456. 127 indexed citations
13.
Kodach, Liudmila L., Carina L. Bos, Nelsón Durán, et al.. (2005). Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis. 27(3). 508–516. 122 indexed citations
14.
Ferreira, Carmen Verı́ssima, Carina L. Bos, Henri H. Versteeg, et al.. (2004). Molecular mechanism of violacein-mediated human leukemia cell death. Blood. 104(5). 1459–1464. 115 indexed citations
15.
Bos, Carina L., Dick J. Richel, Tita Ritsema, Maikel P. Peppelenbosch, & Henri H. Versteeg. (2003). Prostanoids and prostanoid receptors in signal transduction. The International Journal of Biochemistry & Cell Biology. 36(7). 1187–1205. 293 indexed citations
16.
Branger, Judith, Bernt van den Blink, Sebastiaan Weijer, et al.. (2002). Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia. The Journal of Immunology. 168(8). 4070–4077. 203 indexed citations
17.
Vervenne, Walter L., et al.. (2002). Farnesyl Protein Transferase Inhibition Interferes with Activation of MAP Kinase Family Members in Human Peripheral Blood Monocytes. Molecular Medicine. 8(12). 857–862. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shiro Nakaike Breakdown of academic impact, for papers by Song Xu Breakdown of academic impact, for papers by Lorenza Trabalzini Breakdown of academic impact, for papers by Bruna Pucci Breakdown of academic impact, for papers by Xin Wu Breakdown of academic impact, for papers by Hui‐Chiu Chang Breakdown of academic impact, for papers by Lucia Trevisi Breakdown of academic impact, for papers by My‐Hanh Lam Breakdown of academic impact, for papers by Byung‐Doo Hwang Breakdown of academic impact, for papers by Mohamed Ouzzine
Rankless by CCL
2026